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Abstract
Background: Expansion protocols aim at both increasing the number of umbilical cord blood (UCB) hematopoietic
stem cells and progenitor cells (HSPCs) and reducing the period of neutropenia in UCB HSPC graft. Because
glycosaminoglycans (GAGs) are known to be important components of the hematopoietic niche and to modulate
growth factor effects, we explored the use of GAG mimetic OTR4131 to potentiate HSPC’s in vitro expansion and in
vivo engraftment.
Methods: UCB CD34+ cells were expanded with serum-free medium, SCF, TPO, FLT3-lig and G-CSF during 12 days
in the absence or the presence of increasing OTR4131 concentrations (0-100 μg/mL). Proliferation ratio, cell viability
and phenotype, functional assays, migration capacity and NOD-scid/γc-/- mice engraftment were assessed after
expansion.
Results: At Day 12, ratios of cell expansion were not significantly increased by OTR4131 treatment. Better total
nucleated cell viability was observed with the use of 1 μg/mL GAG mimetic compared to control (89.6 % ± 3.7 %
and 79.9 % ± 3.3 %, respectively). Phenotype analysis showed a decrease of monocyte lineage in the presence of
OTR4131 and HSPC migration capacity was diminished when GAG mimetic was used at 10 μg/mL (10.9 % ± 4.1 %
vs. 52.9 % ± 17.9 % for control). HSPC clonogenic capacities were similar whatever the culture conditions. Finally, in
vivo experiments revealed that mice successfully engrafted in all conditions, even if some differences were
observed during the first month. Three months after graft, bone marrow chimerism and blood subpopulations
were similar in both groups.
Conclusions: UCB HSPCs ex-vivo expansion in the presence of OTR4131 is a safe approach that did not modify cell
function and engraftment capacities. In our experimental conditions, the use of a GAG mimetic did not, however,
allow increasing cell expansion or optimizing their in vivo engraftment.
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Background
Umbilical cord blood (UCB) is an alternate source of
both hematopoietic stem cells and progenitor cells
(HSPCs) that is used to treat patients with hematologic
diseases. Despite numerous advantages of UCB, such as
easy access and lack of ethical issues, UCB HSPC trans-
plantation has been hampered by the lower HSPC num-
ber compared with that in bone marrow or peripheral
blood stem cells, leading to a longer period of post-
transplant neutropenia and a delayed immunological re-
constitution [1]. To overcome the limitation of cell
quantity and maturity, many strategies have been pro-
posed and developed to expand UCB HSPCs ex vivo
and optimize the UCB transplantation process [2]. The
advanced understanding of HSPC biology induced the
development of numerous ex vivo amplification proto-
cols based on growth factors and cocultivation. Using
hematopoietic specific cytokines was the first and easi-
est method to amplify HSPCs [3, 4]. Based on this, we
used a serum-free ex vivo culture protocol involving a
cocktail of four selected cytokines (SCF, TPO, FLT3-lig,
and granulocyte colony-stimulating factor (G-CSF)) de-
veloped by the Dazey laboratory and currently evaluated
in clinical trials (NCT01034449), which have already
demonstrated in vitro and in vivo relevant results [5].
An important milestone of such amplification protocols
is not only to increase the amount of cells but also their
survival quality, in order to optimize their in vivo en-
graftment in the medullary compartment.
The bone marrow stem cell niche is a complex struc-
ture, composed of cells, cytokines, and extracellular matrix
(ECM) whose glycosaminoglycans (GAGs) are known to
play an important role both in spatial organization and in
interaction with cells and hematopoietic cytokines [6, 7].
In this site, the major GAGs are heparan sulfate (HS) and
chondroitin sulfate (CS) [8]. Their use in ex vivo HSPC
amplification protocols could participate in a better ampli-
fication process in terms of cell quality and quantity.
Indeed, HS and CS are long polysaccharides composed of
specific disaccharide building blocks, characterized by
complex structures due to heterogeneity in glucosidic
linkages, hydrophobic regions, and sulfatation patterns
[9]. All properties of HS define the anionic interaction and
hydrogen binding protein. Thus, HS could constitute a
low-affinity receptor to heparin-binding proteins which
could be necessary for signal transduction, such as de-
scribed previously for syndecans on hematopoietic pro-
genitor cells [10].
Owing to these properties, a family of chemically-
engineered analogs of endogenous GAGs has been de-
veloped, named ReGeneraTing Agents® (RGTA®; OTR3
SARL, Paris, France) [11, 12]. GAG mimetic syntheses
are performed according to Good Manufacturing Prac-
tice grade, an essential point in human clinical issues. It
was recently demonstrated that a specific GAG mimetic,
namely OTR4131, is able to potentiate properties of dif-
ferent stem and progenitor cells: injection of this mi-
metic into mice was associated with mobilization of
hematopoietic stem cells (HSCs) from the bone marrow
to peripheral blood, according to an in vivo modification
of the SDF-1 gradient [13].
According to the functional relevance of these GAG/
cytokine interactions in HSPC homeostasis regulation,
we investigated in the present study whether the associ-
ation of a GAG mimetic could optimize the in vitro clinical
UCB-derived HSPC amplification procedure. Moreover,
whereas HSPC graft with intensive therapies (chemother-
apy and/or total body irradiation) induced bone marrow
lesions [14], we tested whether the presence of GAG mi-
metics during the UCB-derived HSPC expansion step
could optimize the UCB HSPC in vivo engraftment.
Methods
HSPC purification, cryopreservation, and thawing
UCB units from normal full-term deliveries were obtained
from Saint-Louis Hospital Cord Blood Bank (Paris, France)
after mothers’ written informed consent, in accordance
with health authorities (French Cord Blood Network,
Paris, France). The study was approved by the Saint-Louis
Hospital Biological Resource Center Scientific Council
(authorized by the French Ministry of Research under
number AC-2008-376). Mononuclear cells were separated
with lymphocyte separation medium (Eurobio, Courta-
boeuf, France). CD34+ HSPCs were isolated by supermag-
netic microbead with a QuadroMAC Separator (Miltenyi
Biotech, Paris, France) according to the manufacturer’s in-
structions. CD34 purified cells were kept frozen in liquid
nitrogen and thawed on the day of amplification.
RGTA®-OTR4131
RGTA®-OTR4131 mimetic was obtained from OTR3
SARL. RGTA®-OTR4131 is a dextran derivative, com-
posed of about 250 glucosidic units, with carboxylate
and sulfate degrees of substitution close to those of hep-
arin, except for a lower degree of the acetyl group [11, 12].
When needed, OTR4131 was coupled with the fluorescent
dye Alexa Fluor 647® (AF647-OTR4131) and image ac-
quisition was made with Nikon BioStation IM (Nikon,
Champigny sur Marne, France). OTR4131 compound
was used during HSPC expansion at concentrations
ranging from 0 to 100 μg/ml.
Expansion protocol
Complete medium was composed of serum-free HP01
culture medium (Macopharma, Tourcoing, France) con-
taining 100 ng/ml SCF, 20 ng/ml TPO, 100 ng/ml FLT3-
Lig (all provided by Peprotech, Neuilly sur Seine,
France), and 10 ng/ml Filgrastim (Zarzio®; Sandoz,
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Levallois-Perret, France), as described previously [15].
HSPC expansion was initiated by culturing 20 × 103
CD45+/34+ viable purified cells per milliliter in complete
medium at 5 % CO2 in water-saturated air for 6 days in
24-well plates. Cultured cells were then transferred into
six-well plates (all from Becton Dickinson, Le Pont De
Claix, France) for another 6 days, with fresh complete
medium (4/1 v/v). Cell phenotype was performed at day
12 by flow cytometry analysis according to the antigen
panel presented in Table 1. Cell expansion was expressed
as the ratio between absolute cell numbers at day 12 di-
vided by absolute cell numbers at day 0.
Flow cytometry analysis
Cells were washed in phosphate-buffered saline and
incubated for 30 minutes at 4 °C with a combination of
monoclonal antibodies against human cell surface anti-
gens as presented in Table 1. Antibodies were purchased
Table 1 Details of CD used for each cell population described
Population Panel Percentage expressed in
In vitro analysis
Enriched HSC CD45/34/90 CD45
Myeloid progenitor CD45/34hi/33 Cells
Myeloid precursor CD45/34lo/33 Cells
Monocyte lineage CD45/34–/33/14 Cells
Neutrophil lineage CD45/34–/14–/33 Cells
B-lymphocyte progenitor CD45/34/10/19 CD45
B-lymphocyte lineage CD45/10/19 CD45
Megakaryocyte precursor CD45/34/41/42 Cells
Immature platelet CD45/41/42 Cells
Erythroid lineage CD45/36/235a Cells
Immature erythrocyte CD45–/36/235a Cells
Mice analysis
Hematopoietic cells CD45 Cells
HSPCs CD45/34 CD45







T-lymphocyte progenitor CD45/34/10–/19–/7 CD34
B-lymphocyte progenitor CD45/34/10/19/7– CD34
B-lymphocyte CD45/34–/19/7– CD45
Myeloid progenitor CD45/34hi/33 CD34
Myeloid precursor CD45/34lo/33/15 CD34
Dendritic cell CD45/34–/14/15–/11b/11c CD45
Monocyte CD45/34–/33/14/15– CD45
Neutrophil CD45/34–/33/14–/15 CD45
Megakaryocyte precursor CD45/34/41a/42 CD45
Platelet CD45–/41a/42 Cells
Erythroid lineage CD45/36/235a CD45
Erythrocyte CD45–/235a Cells
CD cluster of differentiation, CLP common lymphoid progenitor cells, CMP common myeloid progenitor cells, GMP granulocyte macrophage progenitor cells,
hi high, HSC hematopoietic stem cells, HSPC hematopoietic stem cell and progenitor cell, lo low, MEP megakaryocyte erythroid progenitor cells,
MPP multipotent progenitor cells
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as described: CD36 APC, CD14 PE-Cy7, CD42 PE,
CD33 PE, CD34 APC, CD45 FITC (all from Becton
Dickinson), CD34 Pacific Blue, CD45 Alexa Fluor 700,
CD41 APC, CD90 APC, CD10 PE-Cy7, CD19 PE-Cy7
(all from Biolegend, Saint Quentin en Yvelines, France),
and CD235a PE, 7-AAD (both from Beckmann Coulter,
Villepinte, France). Cells were analyzed on a FACSCanto
II flow cytometer (Becton Dickinson) using Diva soft-
ware (version 6.1.3; Becton Dickinson).
Migration assay
The migration assay was performed in 24-well culture
plates with a 5 μm pore size Transwell (Corning, Tewks-
bury, Massachusetts, USA). SDF-1α (100 ng/ml; R&D
Systems, Lille, France) was added to the lower chamber.
Then 1 × 105 cells per well, washed beforehand, were
placed in the upper compartment and incubated at 37 °
C and 5 % CO2. The percentage of cell migration was
calculated after 6 hours.
Colony-forming unit quantification
Clonogenicity of expanded cells was assessed by
methylcellulose-based semisolid cultures according to
the manufacturer’s protocol (MethoCult®; StemCell
Technologies, Grenoble, France). Viable CD34+/CD45+
cells were seeded in duplicate in six-well culture plates
at 300 cells/ml. Cells were incubated at 37 °C and 5 %
CO2 and colony-forming units (CFUs) were scored using
an inverted microscope after 14 days. Hematopoietic
colonies were identified as follows: colonies containing
both erythroid and myeloid cells (CFU-GEMM); col-
onies containing erythroid cells (CFU-E); myeloid col-
onies of pure granulocytic colonies (CFU-G); monocytic
colonies (CFU-M); and colonies containing both granu-
locytes and monocytes (CFU-GM). Results were
expressed as the CFU number per 1000 CD34+/CD45+
cells.
Animal model
Immunodeficient NOD-scid/γc–/– (NSG) mice (The
Jackson Laboratory, Bar Harbor, Maine, USA) were bred
and maintained in strict accordance with Directive
2010/63/UE. The protocol was approved by the Com-
mittee on the Ethics of Animal Experiments of the
French Ministry of Agriculture (Permit Number:
02447.01). Eight-week old mice were irradiated with
2.25 Gy 24 hours before intravenous injection of 1 × 106
cells expanded in the presence or absence of 1 μg/ml
OTR4131, according to the protocol already described.
The bone marrow, spleen, and thymus were harvested 1
and 3 months later, flushed, and crushed on a 100 μm
strainer before flow cytometer analysis (n = 4 mice per
time point) of different subsets of the hematopoietic
population according to clusters of differentiation, as
presented in Table 1. Chimerism was evaluated by the
percentage of human CD45+ cells in different organs.
Statistical analysis
Data are expressed as the mean ± standard deviation.
Mean value comparisons were assessed by a t test on
paired samples. All calculations were performed using
MedCalc® (version 7.2.1.0; MedCalc Software, Ostend,
Belgium). The reported p values are two-sided and sig-
nificance was defined as p <0.05.
Results
In vitro evaluation of expanded HSPCs
We first aimed at evaluating how GAG mimetic inter-
acts with HSPCs. To this aim, 10 μg/ml AF647-OTR4131
was added to culture medium, and fluorescence was
evaluated at days 3, 6, 9, and 12. AF647-OTR4131 fluor-
escent compound was shown to interact with HSPCs,
and was found on the surface and in the cytoplasm of
HSPCs whatever the time point considered. Intracellular
staining was found to increase with time (Fig. 1a–d).
Purified UCB HSPC expansion was then performed,
following a 12-day process. CD34+/CD45+ cell purity
and viability before culture were 88.1 ± 7.7 % and 96.0 ±
1.9 %, respectively (n = 9). At day 12 the amplification
ratios of total nucleated cells (TNC) and of CD34
+/CD45+ cells were evaluated in the absence or the pres-
ence of increasing OTR4131 concentrations (from 1 ng/
ml to 100 μg/ml). The mean TNC expansion ratio was
390.0 ± 147.1 for control, and ranged from 401.0 to
549.2 in the presence of OTR4131 (p >0.05 for all condi-
tions). At the CD34+/CD45+ level, expansion in complete
medium was 49.0 ± 28.3 at day 12, and between 45.7 and
55.1 at the tested OTR4131 concentrations (p >0.05,
Fig. 1e).
After 6 days of expansion, TNC or CD34+/CD45+ cell
viabilities were similar whatever the conditions. How-
ever, a higher TNC viability was obtained in the pres-
ence of 1 μg/ml OTR4131 after 12 days of expansion,
with 89.6 ± 3.7 % compared with 79.9 ± 3.3 % in control
conditions (p = 0.0024). CD34+/CD45+ viability followed
the same trend in the presence of OTR4131, while not
reaching significant statistical difference (Fig. 1f ).
In order to determine the impact of OTR4131 on the
outcome of cell phenotype during the amplification
phase, cell phenotypes were analyzed after 12 days of ex-
pansion. Results are summarized in Fig. 2. The percent-
age of CD34+/CD45+ HSPCs was 14.1 ± 11.4 % in
control conditions, and ranged from 5.6 to 31.3 % in the
presence of OTR4131 (p >0.05 for all tested conditions).
Within the CD34+/CD45+ cell population, the number
of more immature CD34+/CD45+/CD90+ HSCs was also
similar in the presence or absence of OTR4131 during
the expansion protocol. Analysis of the committed
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myeloid subpopulations showed that only the monocyte
percentage decreased in the presence of 100 μg/ml
OTR4131 compared with control (35.1 ± 6.3 % vs.
26.3 ± 2.7 %, p = 0.04). The lymphoid lineage was not
significantly modified whatever the experimental
conditions, even if a slight decrease of B-lymphoid pro-
genitors was observed with 10 μg/ml OTR4131. Platelet
and erythroid lineages were also not affected.
HSPC clonogenic capacities were also assessed at the
end of the expansion protocol. After 14 days of semi-
solid culture of 1000 viable CD34+/CD45+ cells, the
numbers of CFU-G, CFU-M, CFU-GM, CFU-E, and
CFU-GEMM were not significantly different between
control and increasing OTR4131 concentration (Fig. 3a),
thus suggesting that HSC expansion in the presence of
GAG mimetic does not affect HSPC differentiation
properties.
Interestingly, high OTR4131 concentrations were
shown to diminish cell migration capacities toward the
SDF-1 gradient. At 10 and 100 μg/ml OTR4131, the per-
centages of migration were 10.9 ± 4.1 % and 13.7 ±
12.9 %, respectively, compared with 52.9 ± 17.9 % for
Fig. 1 Effect of increasing concentrations of OTR4131 on HSPC proliferation and viability. a–d HSPC culture in the presence of 10 μg/ml AF647-OTR4131
at 3, 6, 9, and 12 days. Upper panel: phase contrast; middle panel: Cy5 staining; lower panel: merge (scale bar = 50 μm). e TNC and CD34+/CD45+ cell
ratios between day 0 and day 12 (n = 9 for 0 to 1 μg/ml and n= 4 for 10 and 100 μg/ml OTR4131 concentrations). f TNC and CD34+/CD45+ cell viability
at day 6 (white bars, n= 7) and day 12 (dark bars, n = 5). *p = 0.0024. TNC total nucleated cells
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controls (p = 0.0038 and p = 0.0120, respectively, Fig. 3b).
This effect was not observed when GAG mimetic was
used at a concentration of 1 μg/ml, for which HSPC
migration was similar to that of controls.
In vivo engraftment of expanded HSPCs
Engraftment efficiency of expanded HSPCs and chime-
rism in mice hematopoietic organs were compared be-
tween controls and cells expanded with 1 μg/ml
OTR4131. This concentration was chosen because 1 μg/
ml OTR4131did not affect the main tested parameters
(amplification ratio, phenotype, migration, and clono-
genicity) and tended to increase cell viability.
Data of bone marrow reconstitution 1 month after
transplantation are summarized in Fig. 4. The percent-
ages of chimerism (CD45+ cells) were no different
between controls (1.6 ± 0.5 %) and 1 μg/ml OTR4131
(2.3 ± 1.0 %) expanded HSPCs. However, HSPCs and
HSCs (defined as CD45+/CD34high cells) were lower in
the OTR4131 group than in controls, with 5.6 ± 1.9 %
vs. 10.8 ± 2.6 % (p = 0.0174) and 1.7 ± 1.0 % vs. 4.1 ±
1.1 % (p = 0.0181), respectively. No significant statistical
differences were observed between the two groups re-
garding the various immature progenitors, such as mul-
tipotent progenitor cells, common myeloid progenitor
cells, common lymphoid progenitor cells, megakaryo-
cyte erythroid progenitor cells, and granulocyte macro-
phage progenitor cells. Similar results were obtained
for lymphoid and megakaryocyte lineages. Some dif-
ferences were obtained for myeloid lineage, however, with
a decreased percentage of myeloid progenitors (CD45+/
CD34high/CD33+) in the OTR4131 group (14.7 ± 9.4 %)
compared with controls (36.2 ± 5.2 %) (p = 0.0072), associ-
ated with an increased percentage of myeloid precursor
Fig. 2 Flow cytometry analyses of expanded HSPCs at day 12 (n = 4). a. Percentages of myeloid and lymphoid lineage after expansion. b. Percentages
of enriched HSC, megakaryocyte lineage and erythoid lineage after expansion. Each cell population was described following the cluster of
differentiation presented in Table 1. *p <0.05. HSC hematopoietic stem cells
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(CD45+/CD34low/CD33+/CD15+): 56.3 ± 15.5 % and 23.1 ±
8.1 %, respectively (p = 0.0080). Mature myeloid cell, neu-
trophil, and dendritic cell percentages were not modified,
while monocytes were decreased in the OTR4131 group
(0.2 ± 0.2 %) compared with the control group (0.8 ± 0.2 %)
(p = 0.0077). Lastly, the erythroid lineage increased in the
OTR4131 group, particularly for immature erythroid cells
(CD45–/CD36+/CD235+), with percentages of 0.086 ±
0.061 % compared with 0.010 ± 0.003 % in the control
group (p = 0.0477).
The bone marrow, thymus, and spleen chimerisms
(CD45+ cells) were analyzed in mice 3 months after ex-
panded cell transplantation. No statistical difference was
shown between controls and OTR4131 expanded cells,
with a percentage of human cells of 5.8 ± 5.4 % vs. 15.0 ±
10.1 % in the bone marrow, of 21.2 ± 36.0 % vs. 11.7 ±
6.6 % in the thymus, and of 1.6 ± 0.8 % vs. 3.4 ± 2.0 %
in the spleen, respectively. These results were consist-
ent with similar percentages of hematopoietic lineages
in the bone marrow in both groups (Fig. 4). Thymus
and spleen explorations also showed that mice equally
reconstitute progenitor and/or mature lineages (data
not shown).
Discussion
Since the first definition of the stem cell niche intro-
duced by Schofield [16], the knowledge of the micro-
environment role toward hematopoiesis has evolved
extensively. Cytokines and proteoglycans have been
shown to play an important role in HSPC maintenance
and differentiation. The role of proteoglycans has been
extended to support endogenously expressed hematopoietic
cytokines on the surface of stromal cells, in ECM, and in
solution [17, 18]. Moreover, a high fraction of total GAGs
synthesized by stromal or hematopoietic cells is present in
solution rather than on the stromal layer [19–21]. In the
bone marrow niche, it is well known that GAGs play an
important role in spatial organization and in interaction
with hematopoietic cytokines [6, 7, 22]. For example, it
was demonstrated that Glypican-3 proteoglycan is in-
volved in HSC homing and maintenance mechanism, im-
plicating interactions between the chemokine CXCL12
and its receptor CXCR4 [23]. Moreover, the relevance of
GAG in the homeostasis of medullar microenvironment is
attested by the demonstration that heparanase activity
regulates retention and proliferation of primitive Sca-1/c-
Kit/Lin– cells in mice bone marrow, whereas a reduction
in the overall leukocyte cellularity bone marrow is ob-
served. This suggests an important role of heparanase, and
accordingly of HS, in hematopoietic progenitor cell regula-
tion and control of the primitive cell pool size [24]. More
recently, Saez et al. [25] demonstrated that inhibition of
HS production in bone marrow osteolineage Mx1 stromal
cells results in a disruption of HSC interactions within the
niche and their egress into the peripheral circulation.
HSs, more particularly, are part of GAG subsets that
can maintain HSPCs for in vitro long-term culture [18].
Several studies have also demonstrated an effect of hep-
arin or noncharacterized human stromal-derived HS on
different kinds of hematopoietic progenitors. Their
presence during ex vivo amplification protocols has
thus improved both megakaryocytic maturation and
the amplification ratio [26–28]. For all these reasons,
we hypothesized that OTR4131, a sulfated GAG mi-
metic, could have an interest in UCB HSPC amplifica-
tion protocols.
These protocols were initially developed to overcome
some limitations of UCB graft, such as delayed
Fig. 3 In vitro functional properties of expanded cells. a Number of CFU-GEMM, CFU-E, CFU-G, CFU-M, and CFU-GM per 1000 viable CD34+/CD45
+ cells (n = 4, *p <0.05). Error bars correspond to the standard deviation. b Migration capacity, expressed as the percentage of migration of total
cells in front of a SDF-1 gradient (p = 0.0038 and p = 0.012 respectively, n = 4). CFU-E colony-forming units of erythrocytes, CFU-G colony-forming
units of granulocytes, CFU-GEMM colony-forming units of granulocytes, erythrocytes, monocytes, and megakaryocytes, CFU-GM colony-forming
units of granulocytes and monocytes, CFU-M colony-forming units of monocytes
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neutropenia and the need for transfusion caused by low
number and immaturity of HSPCs [1, 2]. According to
the World Health Organization, more than 25 clinical
trials have currently been initiated.
The present study deals with the GAG mimetic
OTR4131, a well-characterized synthetic polymer
RGTA®. OTR4131 was here used for ex vivo amplifica-
tion of UCB-derived HSPCs during 12 days. First of all,
we observed an important interaction between fluores-
cent OTR4131 (at 10 μg/ml) and HSPCs from 2 days of
culture. Below this concentration, the fluorescent
OTR4131 was not detectable with our fluorescent
microscope. Concerning the amplification ratio, no dif-
ference was observed in the presence or absence of
OTR4131, except for a better TNC viability at 1 μg/ml
OTR4131. A similar increase of viability was observed
on rat skin fibroblasts with 1 μg/ml OTR4120, another
GAG mimetic compound. In this study, Yue et al. [29]
concluded that this effect was related to a regulation of
the premitochondrial death cascade with an inhibition
of lysosomal cathepsin activities and a protection of
the lysosome from membrane disruption. In that work,
the RGTA® effect was associated with a reduction of
intracellular reactive oxygen species levels and an
Fig. 4 Bone marrow NSG mice reconstitution after transplantation of expanded HSPCs. a One month after transplantation, human hematopoietic
cells were characterized in mice bone marrow by flow cytometry. Cell markers are presented in Table 1 (n = 4). *p <0.05. b The same analyses
were performed 3 months after transplantation (n = 3). CLP common lymphoid progenitor cells, CMP common myeloid progenitor cells, GMP
granulocyte macrophage progenitor cells, hi high, HSC hematopoietic stem cells, HSPC hematopoietic stem cell and progenitor cell, lo low, MEP
megakaryocyte erythroid progenitor cells, MPP multipotent progenitor cells
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inhibition of mitochondrial membrane potential col-
lapse [29]. Moreover, we observed a decrease in the mi-
gration of amplified HSPCs with OTR4131, which
could be explained by the elevated quantity of OTR4131
on the HSPC surface, blocking SDF-1α chemoattraction
by a sequestration effect [30]. Based on their phenotype or
their clonogenic capacity, the composition of amplified
HSPC populations was similar with or without OTR4131,
except for an isolated decrease in monocyte lineage.
Furthermore, according to in vitro results of 1 μg/ml
OTR4131 mimetic, the effect on NSG graft experiments
was limited after 1 month: the different populations
of HSPCs (CD34+ or CD34+high) were statistically di-
minished in the OTR4131 group; and we observed
an increase in the percentage of myeloid precursor
cells and immature fraction of erythrocyte lineage.
This modification was not stabilized in long-term
graft whatever the lineage, and we therefore cannot
conclude about a lasting change. These data suggest
that GAGs probably impact cell differentiation at the
level of long-term culture initiating cells (LTC-ICs)
rather than at that of precursor or immature HSC.
This hypothesis may also explain the modification
observed on myeloid precursors, progenitors, and
mature cells. These results are consistent with those
already reported by Gupta et al. [17] during LTC-IC
in vitro culture in the presence of various GAGs.
Even if the benefits of this specific mimetic on amplifi-
cation protocols were too slight, however, we will discuss
the interest of screening new compounds with more ef-
fective structural and functional features that would
present an interest for in vitro or in vivo further uses.
Accordingly, in the literature, GAG effects are linked to
their structural signature. Gupta et al. [17, 18] compared
the sulfatation profile of HS derived from a hematopoiesis
supportive and nonsupportive cell line and found that a
fine pattern of sulfate substitution is necessary to bind to
hematopoietic cytokines such as interleukin-3, macro-
phage inflammatory protein-1α, and thrombospondin.
Moreover, sulfatation pattern alteration has been found to
reduce the ability of heparin, a more extensively sulfated
form of HS, to maintain LTC-ICs [18, 31]. These struc-
tural characteristics provide specific binding properties to
proteins. Thereby GAG-bind proteins are protected
against proteases and interactions with their receptors are
facilitated [9, 32, 33]. For example, fine characterization of
the binding of heparin to G-CSF demonstrated the im-
portance of sulfate groups since 2,3-O-sulfate groups
are more important than N-sulfate groups in heparin–
G-CSF interaction [34]. Heparin-induced leukocytosis
requires glucosamine 6-O-sulfation and is caused by
blockade of L-selectin-mediated, P-selectin-mediated,
and CXCL12-mediated leukocyte trafficking [35]. Fi-
nally, it was demonstrated that accumulated overly
sulfated extracellular HS, in patients suffering from
Mucopolysaccharidosis I, alters cytokine gradient for-
mation since they abnormally bind and sequester
CXCL12. This induces limited hematopoietic migra-
tion and engraftment, providing a potential mechanism
for the limited scope of HSPC transplantation in
Hurler syndrome [36].
Conclusion
Taking into consideration the development of ex vivo
amplification UCB-derived HSPC strategy, the aim of
this study was to potentiate a protocol based on a
serum-free medium added with heparin-binding cyto-
kines with a GAG mimetic named OTR4131. In our ex-
perimental conditions, GAG mimetic in medium during
cell amplification seems not to be the best strategy.
However, it could be interesting to design and screen
several GAG mimetics with different sulfatation patterns
that could be optimized to improve HSPC amplification.
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